根治性前列腺切除术后新发生化复发的前列腺癌:PSMA PET/CT与单独CT的检出率及治疗影响比较
回顾性研究纳入59例根治性前列腺切除术后新近生化复发的前列腺癌患者(平均PSA 1.96±1.64 ng/mL),分别接受68Ga-PSMA-11(n=36)或18F-PSMA-1007(n=23)PET/CT。PSMA PET/CT在病灶水平(99.3% vs 50.7%,p<0.0001)和患者水平(84.7% vs 49.2%,p<0.0001)检出率均显著高于单独CT,并在38例中检出更多病灶,其中22例治疗策略因此改变。
要点
- PSMA PET/CT患者水平检出率84.7%,显著高于单独CT的49.2%(p<0.0001)。
- CT检出的全部病灶均被PSMA PET/CT检出。
- PSMA PET/CT在38例中检出更多病灶,其中22例治疗策略改变。
核心结论
- PSMA PET/CT在根治性前列腺切除术后生化复发的前列腺癌检出上优于单独CT,并在相当数量患者中提供了额外治疗选择。
研究设计与样本
- 回顾性研究纳入59例根治性前列腺切除术后新近生化复发的前列腺癌患者,平均PSA 1.96±1.64 ng/mL。
- 患者接受68Ga-PSMA-11 PET/CT(n=36)或18F-PSMA-1007 PET/CT(n=23)。
- PET/CT与CT图像由两名医师分别评估前列腺癌病灶数量、类型和定位。
- 以组织病理学、随访影像及挽救性放疗后PSA水平作为参考标准。
- 采用McNemar检验比较检出率,并在虚拟多学科肿瘤委员会中评估基于CT与PET/CT分期差异的治疗方案变化。
关键影像表现/征象
- 59例患者中50例共检出142个病灶。
- PSMA PET/CT检出50例患者中的141个病灶(99.3%),CT检出29例患者中的72个病灶(50.7%)。
- 9例患者(15.3%)两种检查均未检出复发灶。
- CT检出的全部病灶均被PSMA PET/CT检出。
- 38例患者中PSMA PET/CT较单独CT检出更多病灶。
诊断标准与关键数值
- 病灶水平分析:PSMA PET/CT检出率99.3%(141/142) vs 单独CT 50.7%(72/142),p<0.0001。
- 患者水平分析:PSMA PET/CT检出率84.7%(50/59) vs 单独CT 49.2%(29/59),p<0.0001。
- 68Ga-PSMA与18F-PSMA PET/CT分别均显著优于单独CT(p<0.0001)。
临床应用与阅片要点
- 在根治性前列腺切除术后生化复发评估中,PSMA PET/CT较单独CT可检出更多病灶并改变部分患者的治疗策略。
- 38例中PSMA PET/CT检出更多病灶,其中22例治疗策略因此改变。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To compare prostate specific membrane antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) and computed tomography (CT) alone for the detection of biochemical recurrence of prostate cancer (PCa) and effect on treatment.
METHODS: This retrospective study included 59 patients with recently recorded biochemical recurrence of PCa (mean PSA 1.96 ± 1.64 ng/mL) after radical prostatectomy. Patients received PET/CT with either 68Ga-PSMA-11 (n = 36) or 18F-PSMA-1007 (n = 23). PET/CT and CT images were evaluated separately in regard to PCa lesion count, type, and localisation by two physicians. Histopathology, follow-up imaging and PSA levels after salvage irradiation served as reference standard. A McNemar test was used to compare detection rates. Changes in therapeutic approaches based on staging differences between CT alone and PET/CT were assessed in a virtual multidisciplinary tumour board.
RESULTS: There were 142 lesions in 50 of 59 patients. PSMA PET/CT detected 141 lesions (99.3 %) in 50 patients (84.7 %), while CT detected 72 lesions (50.7 %) in 29 patients (49.2 %). A significantly higher detection rate of PSMA PET/CT was observed on a lesion-based analysis (p < 0.0001) and on a patient based analysis (p < 0.0001). Herein, both 68Ga- and 18F-PSMA PET/CT performed significantly better than CT alone (p < 0.0001, respectively). In 9 patients (15.3 %) no relapse was detectable by either modality. All lesions detected by CT were also detected by PSMA PET/CT. In 38 patients PSMA PET/CT detected more lesions than CT alone, altering the treatment approach in 22 of these patients.
CONCLUSION: PSMA PET/CT is superior to CT alone in detecting biochemical recurrence in PCa patients after radical prostatectomy and offered additional therapeutic options in a substantial number of patients.
引用
- Morawitz J, Kirchner J, Lakes J, et al. PSMA PET/CT vs. CT alone in newly diagnosed biochemical recurrence of prostate cancer after radical prostatectomy: Comparison of detection rates and therapeutic implications. Eur J Radiol. 2021. PMID: 33485127. doi:10.1016/j.ejrad.2021.109556
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。